DOI QR코드

DOI QR Code

Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology

  • Kucukoner, Mehmet (Department of Medical Oncology, Dicle University) ;
  • Isikdogan, Abdurrahman (Department of Medical Oncology, Dicle University) ;
  • Yaman, Sebnem (Ankara Numune Hospital) ;
  • Gumusay, Ozge (Gazi University) ;
  • Unal, Olcun (9 Eylul University) ;
  • Ulas, Arife (Ankara Oncology Hospital) ;
  • Elkiran, Emir T. (Firat University) ;
  • Kaplan, Muhammed A. (Department of Medical Oncology, Dicle University) ;
  • Ozdemir, Nuriye (Ankara Numune Hospital) ;
  • Inal, Ali (Department of Medical Oncology, Dicle University) ;
  • Urakci, Zuhat (Department of Medical Oncology, Dicle University) ;
  • Buyukberber, Suleyman (Gazi University)
  • Published : 2012.08.31

Abstract

Background: The aim of this study was to evaluate the efficacy and toxicity of long-term, low-dose oral etoposide as an advanced treatment option in patients with platinum resistant epithelial ovarian cancer. Materials and Methods: For the purposes of this study, 51 patients with histologically-confirmed, recurrent or metastatic platinum-resistant epithelial ovarian cancer (EOC) treated at six different centers between January 2006 and January 2011 were retrospectively evaluated. Patients were treated with oral etoposide (50 mg/day for a cycle of 14 days, repeated every 21 days). Results: Among the 51 platinum-resistant patients, 17.6% demonstrated a partial response and 25.5% a stable response. The median progression-free survival (PFS) was 3.9 months (95% CI, 2.1-5.7), while the median overall survival was 16.4 months (11.8.20.9). No significant relationship was observed between the pre-treatment CA 125 levels, post-treatment CA-125 levels and the treatment response rates (p=0.21). Among the 51 patients who were evaluated in terms of toxicity, grade 1 or 4 hematologic toxicity was observed in 19 (37.3%); and grade 1-4 gastrointestinal toxicity occurred in 15 patients (29.4%). Conclusions: Chronic low-dose oral etoposide treatment is generally effective and well-tolerated in platinum-resistant ovarian cancer patients.

Keywords

Ovarian cancer;oral etoposide;toxicity;PFS

References

  1. Bast RC Jr, Knapp RC (1985). Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Euro J Obstet Gynecol Reprod Biol, 19, 354. https://doi.org/10.1016/0028-2243(85)90130-3
  2. Baur M, Schernhammer E, Gneist M, et al (2005) Phase I/ II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br J Cancer, 92, 1019-25. https://doi.org/10.1038/sj.bjc.6602427
  3. Cannistra SA, Gershenson DM, Recht A (2011). Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: Devita VT, Lawrence T, and Rosenberg SA, editors. Cancer: Principles and Practise of Oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins. 1368-91 .
  4. De Wit R, Van der Burg ME, Van den Gaast A, et al (1994). Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol, 5, 656-7. https://doi.org/10.1093/oxfordjournals.annonc.a058942
  5. Garrow GC, Hainsworth JD, Johnson DH, Thomas A, Greco FA (1992). Prolonged administration of oral etoposide in previously treated epithelial ovarian cancer: A phase II trial. Proc Am Soc Clin Oncol, 11, 236.
  6. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992). The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 47, 159-66. https://doi.org/10.1016/0090-8258(92)90100-W
  7. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225. https://doi.org/10.3322/caac.20006
  8. Kavanagh JJ, Tresukosol D, Gonzalez De Leon C, et al (1995). Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer, 5, 351-4. https://doi.org/10.1046/j.1525-1438.1995.05050351.x
  9. Maurie Markman, Thomas Hakes, Bonnie Reichman, et al (1992). Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol, 119, 55-7. https://doi.org/10.1007/BF01209489
  10. M K Tuxen, B Lund, O P Hansen, K Bertelsen, M Hansen (1997). Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease. Int J Gynecol Cancer, 7, 213-7. https://doi.org/10.1046/j.1525-1438.1997.00443.x
  11. Naumann RW, Coleman RL (2011) Management strategies for recurrent platinum-resistant ovarian cancer. Drugs, 71, 1397-12. https://doi.org/10.2165/11591720-000000000-00000
  12. Rose PG, Blessing JA, Mayer AE, Homesley HD (1998). Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group Study. J Clinical Oncol, 16, 405-10. https://doi.org/10.1200/JCO.1998.16.2.405
  13. Rustin GJ, Van Der Burg ME (2009). A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators. Proc Am Soc Clin Oncol, 27, 18. https://doi.org/10.1200/JCO.2009.22.4626
  14. Slevin ML, Clark PI, Joel SP, et al (1989). A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung. J Clin Oncol, 7, 1333-40. https://doi.org/10.1200/JCO.1989.7.9.1333
  15. Suleyman A, Pinar S, Yeşim E, Adnan A, Erkan T (2003) Oral etoposide in platinum-resistant epithelial ovarian cancer. Am J Clinical Oncol, 26, 358-62.
  16. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  17. Toffoli G, Corona G, Basso B, Boiocchi M (2004) Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet, 43, 441-66. https://doi.org/10.2165/00003088-200443070-00002
  18. WHO (1979). Handbook for Reporting Results of Cancer Treatment Geneva, Switzerland: World Health Organization, 48.
  19. Yasumizu T, Kato J (1995) Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus. J Obstet Gynecol, 21, 569-76. https://doi.org/10.1111/j.1447-0756.1995.tb00914.x

Cited by

  1. Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5215
  2. Informed walks: whispering hints to gene hunters inside networks’ jungle vol.11, pp.1, 2017, https://doi.org/10.1186/s12918-017-0473-6
  3. Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer pp.0277-3732, 2016, https://doi.org/10.1097/COC.0000000000000281
  4. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer vol.61, pp.3, 2018, https://doi.org/10.5468/ogs.2018.61.3.352